Mesoblast Limited growth

Reported trailing growth, forward expectations and three-year compound growth rates.

Trailing growth

Year over year

Revenue: +1053.2%
EBITDA: -30.2%
EBIT: -71.1%
EPS: +21.7%
Free cash flow: —
Operating cash flow: —

Forward estimates

Revenue: -76.7%
EBITDA: +76.3%
EPS: -42.4%

Three-year CAGR

Revenue: +19.0%
EBITDA: -31.4%
EBIT: +25.8%
Net income: -16.1%
EPS: +5.6%
Free cash flow: -3.9%

Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.